{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:52Z","timestamp":1790312392001,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To estimate a China-specific value-based annual price (P*) for brensocatib 25\u00a0mg added to standard care (SC), compared with SC alone, in adults with frequently exacerbating non-cystic fibrosis bronchiectasis, and to assess how strongly the estimate depends on transferred assumptions linking forced expiratory volume in 1\u00a0s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) to long-term outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A seven-state Markov cohort model with monthly cycles and a lifetime horizon was constructed from the Chinese healthcare system perspective. Chinese sources informed the target population, exacerbation burden, baseline microbiology, background mortality, resource use, costs, discounting, and decision context, while ASPEN supplied the exacerbation rate ratio (0.81) and annual FEV\n                      <jats:sub>1<\/jats:sub>\n                      decline (24\u00a0mL with brensocatib 25\u00a0mg vs. 62\u00a0mL with placebo). In the base case, cohort-mean FEV\n                      <jats:sub>1<\/jats:sub>\n                      was linked to utility and mortality through explicit external mappings. A prespecified structural sensitivity removed both mappings but retained the trial-observed exacerbation benefit. Costs and outcomes were discounted by 4.5% annually. The primary willingness-to-pay (WTP) threshold was CNY 200,000 per quality-adjusted life-year (QALY); uncertainty was examined with a paired 10,000-draw probabilistic sensitivity analysis (PSA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At an illustrative price of CNY 120,000\/year, the FEV\n                      <jats:sub>1<\/jats:sub>\n                      -inclusive base case estimated an incremental cost of CNY 551,543, gains of 0.2761 QALYs and 0.3432 discounted life-years, and 0.57 fewer lifetime exacerbations. These results corresponded to an incremental cost-effectiveness ratio of CNY 1,997,665\/QALY and P* of CNY 11,692\/year. Drug acquisition accounted for almost all of the incremental cost. The PSA median P* was CNY 11,611\/year (95% simulation interval CNY 4,145\u201319,324), and none of 10,000 simulations was cost-effective at CNY 120,000\/year for WTP thresholds up to CNY 300,000\/QALY. Estimates changed little when China-specific demographic and exacerbation inputs were varied. In contrast, removing the FEV\n                      <jats:sub>1<\/jats:sub>\n                      -linked pathway reduced P* to CNY 990\/year, while assuming persistent efficacy after attrition increased it to CNY 24,432\/year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      With inputs localised wherever credible Chinese evidence was available, the FEV\n                      <jats:sub>1<\/jats:sub>\n                      -inclusive base case estimated P* at CNY 11,692\/year for a WTP of CNY 200,000\/QALY. The broad pricing implication was stable, although the exact estimate depended chiefly on the durability and downstream consequences of the 52-week FEV\n                      <jats:sub>1<\/jats:sub>\n                      difference. Both the base case and the key structural sensitivity remained far below the illustrative annual price of CNY 120,000.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1920335","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:16Z","timestamp":1790310376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Value-based pricing of brensocatib for frequently exacerbating non-cystic fibrosis bronchiectasis in China: a China-adapted, FEV1-inclusive time-dependent markov analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Dandan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2021","journal-title":"Lancet Resp. Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/MS9.0000000000004614","article-title":"Brensocatib (brinsupri) first FDA-approved targeted therapy for non-cystic fibrosis bronchiectasis","volume":"88","author":"Babar","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci5040020","article-title":"Healthcare cost and utilization before and after diagnosis of Pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the U.S","volume":"5","author":"Blanchette","year":"2017","journal-title":"Med. Sci. (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1524-4733.2004.72318.x","article-title":"A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease","volume":"7","author":"Borg","year":"2004","journal-title":"VALUE HEALTH"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106526","DOI":"10.1016\/j.rmed.2021.106526","article-title":"Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life","volume":"186","author":"Camac","year":"2021","journal-title":"Resp. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cFrequent Exacerbator Phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"NEW Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"230178","DOI":"10.1183\/16000617.0178-2023","article-title":"Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis","volume":"33","author":"Concei\u00e7\u00e3o","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task Force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12931-022-02023-8","article-title":"Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017: a nationwide population-based cohort study","volume":"23","author":"Feng","year":"2022","journal-title":"Respir. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12889-021-12491-0","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"22","author":"Husereau","year":"2022","journal-title":"BMC Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12890-024-02912-2","article-title":"Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020","volume":"24","author":"Lei","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3784\/jbjc.202305090206","article-title":"Analysis on incidence of death in urban and rural residents in China, 2015\u20132021","volume":"39","author":"Ling","year":"2024","journal-title":"Dis. Surveill."},{"key":"B19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur. Respir. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"300060520931616","DOI":"10.1177\/0300060520932116","article-title":"Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China","volume":"48","author":"Ma","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"964","DOI":"10.18553\/jmcp.2018.18122","article-title":"Health care utilization and expenditures following diagnosis of nontuberculous mycobacterial lung disease in the United States","volume":"24","author":"Marras","year":"2018","journal-title":"J. Manag. Care Spec. P. H."},{"key":"B22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.18553\/jmcp.2026.32.3.392","article-title":"The effectiveness and value of brensocatib for the treatment of non-cystic fibrosis bronchiectasis","volume":"32","author":"McKenna","year":"2026","journal-title":"J. Manag. Care Spec. P. H."},{"key":"B23","volume-title":"Statistical Communiqu\u00e9 of the People\u2019s Republic of China on the 2025 National Economic and Social Development","year":"2026"},{"key":"B24","volume-title":"China Health Statistics Yearbook 2025","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-201","article-title":"European respiratory society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1378\/chest.130.4.1117","article-title":"Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?","volume":"130","author":"Rutten-van M\u00f6lken","year":"2006","journal-title":"CHEST"},{"key":"B27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jval.2010.09.011","article-title":"Predicting EQ-5D values using the SGRQ","volume":"14","author":"Starkie","year":"2011","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med. Decis. Mak."},{"key":"B29","volume-title":"Brensocatib for Non-cystic Fibrosis Bronchiectasis: Effectiveness and Value; Final Report","author":"Wasfy","year":"2025"},{"key":"B30","volume-title":"China Guidelines for Pharmacoeconomic Evaluations 2025 Chinese-English Version","author":"Wu","year":"2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S2213-2600(24)00364-3","article-title":"Baseline characteristics of patients in the Chinese bronchiectasis registry (BE-China): a multicentre prospective cohort study","volume":"13","author":"Xu","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Zhong","year":"2025","journal-title":"Lancet Respir. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:18Z","timestamp":1790310378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":32,"alternative-id":["10.3389\/fphar.2026.1920335"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1920335","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1920335"}}